Catégorie : Non classé
-
Advanced BioDesign Publishes Groundbreaking Study in Cell Chemical Biology Introducing ABD-0171, a Next-Generation ALDH1 Inhibitor for Resistant Solid Tumors
Lyon, France – October 1st, 2025 – – Advanced BioDesign, a biotechnology company pioneering innovative cancer therapies through the inhibition of the aldehyde dehydrogenase, today announced the publication of a landmark study in Cell Chemical Biology presenting ABD-0171, its second-generation inhibitor targeting ALDH1A3, a key enzyme implicated in cancer stemness and therapeutic resistance. The study…
-
Advanced BioDesign to present preclinical proof of concept of ABD-0171 in MSS colorectal cancer at the AACR Annual Meeting 2025
Lyon, March 28th – Advanced BioDesign announced today it will present updated results of its second generation of ALDH1 inhibitor, ABD0171, at the upcoming AACR conference in Chicago, Illinois. The poster presentation will provide proof of concept of the strong synergistic effect of ABD0171 in combination with anti-PD-1 therapy in microsatellite stable (MSS) colorectal cancer,…
-
Advanced BioDesign: A new study published in the Journal of Cellular Molecular Medicine on the involvement of ALDH activity in r/r AML
Lyon (France), October 29, 2024 – Acute Myeloid Leukemia (AML) remains a major medical challenge despite recent advances in targeted molecular therapies. A recent study published in the Journal of Cellular Molecular Medicine1) has highlighted a crucial aspect of leukemic cell resistance to chemotherapy: their increased ability to manage cellular stress and produce reactive oxygen…
Advanced BioDesign 